Risk for use of antidepressants, anxiolytics, and hypnotics in partners of glioma patients—A nationwide study covering 19 years of prescriptions

Jansson, Maria R.N.; Heymann, Annika von; Rasmussen, Birthe Krogh; Albieri, Vanna; Frederiksen, Kirsten; Suppli, Nis P.; Dalton, Susanne Oksbjerg; Johansen, Christoffer; Bidstrup, Pernille Envold

doi:10.1002/pon.4744

Cited by 14 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As the most prevalent cancer in the central nervous system because of the noticeable incidence rate, fast relapse and limited survival , gliomas are characterized by persistent growth, reinforced migration and invasion, and multiple molecular and cytogenetic aberrances . Standard glioma therapy consists of surgery before radiotherapy and chemotherapy .…”

mentioning

confidence: 99%

RETRACTED: CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway

2020

View full text Add to dashboard Cite

Gliomas, the most prevalent cancer in the central nervous system, are characterized by high morbidity and mortality, emphasizing the need to understand their etiology. Here, we report that cyclin‐dependent kinase‐like 5 (CDKL5) is highly expressed in gliomas, and CDKL5 overexpression promotes invasion, proliferation, migration and drug (β‐lapachone) resistance of glioma cells. In vitro, CDKL5 overexpression enhanced invasion, growth and migration of glioma cells, and stimulated the phosphoinositide 3‐kinase (PI3K)/AKT axis. Furthermore, CDKL5 overexpression in vivo promoted glioma proliferation, whereas CDKL5 knockdown had opposing effects. The effect of CDKL5 on drug resistance was eliminated if the PI3K/AKT axis was suppressed, and cisplatin combined with the PI3K/AKT suppressor XL147 remarkably prohibited proliferation in xenografts overexpressing CDKL5. Collectively, our findings suggest that CDKL5 acts through the PI3K/AKT axis in glioma cells, and indicate a possible role for CDKL5 in glioma therapy.

show abstract

mentioning

confidence: 99%

RETRACTED: CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway

2020

View full text Add to dashboard Cite

show abstract

“…Second, due to the registry-based design, partners could not be followed after a change in cohabitation, including death of their cohabiting partner. It is plausible that women may face a higher risk of depression after change of cohabitation status, be it due to their partner's death or for other reasons [48]. Third, the analysis of partners had a lower statistical power than in the male cohort (91,881 vs. 351,263 personyears overall).…”

Section: Discussionmentioning

confidence: 98%

Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

Hartung¹,

Moustsen-Helms

Larsen

et al. 2020

J Cancer Surviv

Self Cite

View full text Add to dashboard Cite

Purpose To estimate the risk of first-time antidepressant prescriptions as a proxy for depression or anxiety and associated risk factors in patients with prostate cancer and their female partners. Methods We followed all men (n = 25,126) and their female cohabiting partners (n = 8785) without a history of cancer or antidepressants from the Danish Diet, Cancer and Health cohort from 1997 to 2014 or 2010, respectively. We estimated the cumulative incidence of first-time antidepressant prescriptions in men with prostate cancer compared with cancer-free men and their respective female partners, using the Danish National Prescription Registry. Sociodemographic, lifestyle-related, and clinical risk factors were assessed using Cox regression models. Results A total of 1828 men were diagnosed with prostate cancer of whom 15% received antidepressants. The unadjusted hazard ratio of antidepressant prescription was 2.18 (95%CI, 1.92, 2.48) for men with prostate cancer and 1.27 (95%CI, 0.87, 1.85) for their partners, compared with cancer-free men and their partners, respectively. After adjusting for sociodemographic, lifestyle-related, and comorbidity factors, this risk was 2-fold to 4-fold increased among patients, but not significantly increased among partners. Significant risk factors among patients were curative and palliative treatment (vs. active surveillance and watchful waiting), nonlocalized disease, and short education. Conclusions Men with prostate cancer have a higher risk of receiving antidepressant medication than cancer-free men. Clinical characteristics can help clinicians in identifying patients at a high risk of depression or anxiety. Implications for Cancer Survivors Men with prostate cancer who experience symptoms of depression or anxiety should seek professional help early on. Patient education could aid in raising awareness and reducing the stigma associated with mental disorders.

show abstract

“…In a Danish population, the prevalence of moderate‐to‐severe depressive symptoms was five times higher among patients with glioma compared with cancer‐free individuals [19]. Jansson et al also found that partners of patients diagnosed with glioma have a four‐fold higher risk of a first prescription for psychotropic medications within the first year of diagnosis [20]. Caregivers describe healthcare professionals as rarely or never inviting them to discuss their caregiving role; hence, they have limited opportunities to talk about challenges in everyday life [21].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a multimodal rehabilitative palliative care programme for patients with high‐grade glioma and their family caregivers

Nordentoft

Dieperink

Johansson³

et al. 2021

Scandinavian Caring Sciences

View full text Add to dashboard Cite

Background Patients diagnosed with high‐grade glioma and their family caregivers often experience intense disease and treatment trajectories. Fluctuations in patient's symptoms lead to enormous burdens for caregivers and the risk of developing symptoms of stress, anxiety, and depression. Aim The study aim is to explore patient and caregiver experiences and evaluate the relevance of and satisfaction with a multimodal rehabilitative palliative care programme for patients diagnosed with a high‐grade glioma and their family caregivers. Methods In a longitudinal multi‐methods study, adult patients with high‐grade glioma (n = 17) and their family caregivers (n = 16) completed a 4‐day residential programme and a 2‐day follow‐up programme 3 months later. Participants completed questionnaires after each programme, scoring relevance and satisfaction on a 5‐point Likert scale. Qualitative data were collected during four evaluation group interviews with patients and caregivers. Results The mean overall satisfaction score was 4.80 (standard deviation [SD], 0.55) for the initial 4‐day programme and 4.28 (SD, 0.83) for the follow‐up programme. Three themes emerged in the evaluation group interviews: (1) meeting peers strengthens social well‐being, (2) the value of information and focusing on individual needs, and (3) accepting life as an unpredictable passage. Conclusion Participants found completing the REHPA‐HGG programme feasible and rated all sessions highly for relevance and satisfaction. Qualitative findings confirm the value of individualised information, acceptance, and peer interactions. Implication for practice A multimodal rehabilitative palliative care programme addressed unmet patient and caregiver needs. Peer‐to‐peer interventions for family caregivers may address individual support needs. Similar programmes may maximise benefit by avoiding planned behaviour changes and enhancing palliative approaches.

show abstract

Risk for use of antidepressants, anxiolytics, and hypnotics in partners of glioma patients—A nationwide study covering 19 years of prescriptions

Abstract: We have documented, for the first time, that the psychological impact of a diagnosis of glioma is such a severe stress exposure that it increases the risk for having medication prescribed to treat symptoms of anxiety, sleep problems, and depression.

Cited by 14 publications

References 36 publications

RETRACTED: CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway

RETRACTED: CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway

Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

Evaluation of a multimodal rehabilitative palliative care programme for patients with high‐grade glioma and their family caregivers

Contact Info

Product

Resources

About